ClinicalTrials.gg
CompletedNCT01227629Updated May 5, 2014Results posted

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

A Phase 2 interventional study of dabigatran with ASA and dabigatran with ASA in Atrial Fibrillation, sponsored by Boehringer Ingelheim. Completed at 38 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-05.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
502
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.

Enrollment
7th of 35
502 · median 174
Started
2003
with 1 other
Phase 2
4 of 35
none open now
Registered
3rd of 35
by date
Lead sponsor
7 of 35
Boehringer Ingelheim

Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 7th largest by enrollment, is one of 2 that started in 2003, is one of 4 in phase 2, and was the 3rd registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing dabigatran in Atrial Fibrillation as a file.
02

Study summary

The purpose of this trial is to evaluate the safety of different doses of BIBR 1048, alone or in combination with acetylsalicylic acid (ASA), as determined by the rates of bleeding and other adverse events.

A secondary objective of this trial is to evaluate the anticoagulant effect of different doses of BIBR 1048, based on the reduction of plasma concentrations of D-dimer, a laboratory marker for activated coagulation in patients with atrial fibrillation (AF), and to correlate bleeding and other events with pharmacokinetic (PK) and pharmacodynamic (PD) data.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-rheumatic atrial fibrillation.
  2. Coronary artery disease (CAD), documented by previous myocard infarction (MI), angina, positive stress test, previous coronary intervention or bypass surgery, or atherosclerotic lesion(s) diagnosed by coronary angiography) is only considered as one of several possible qualifying risk factors. After recruitment of ca. 30%, a protocol amendment 4 was issued so that CAD was only considered as one of several possible qualifying risk factors, 2. see (3 f) below.
  3. An additional risk factor for stroke, i.e. one or more of the following conditions/events:

    1. hypertension (defined as systolic bloodpressure (SBP) > 140 mmHg and/or diastolic bloodpressure (DBP) > 90 mm Hg) requiring antihypertensive medical treatment.
    2. diabetes mellitus (type I and II).
    3. symptomatic heart failure or left ventricular dysfunction ( (EF) \< 40%).
    4. a previous ischemic stroke or .
    5. age greater than 75 years.
    6. history of coronary artery disease (by amendment 4)
  4. Treatment with warfarin or other vitamin K dependent anticoagulants for at least 8 weeks prior to inclusion. (INR) should be within therapeutic range (i.e. INR 2.0 - 3.0) at visit 1 otherwise the visit should be rescheduled.
  5. Age > = 18 years at entry.
  6. Written, .

Exclusion criteria

Exclusion criteria

  1. Valvular heart disease.
  2. Planned cardioversion.
  3. Recent (=\< 1 month) myocardial infarction, stroke or (TIA), or patients who have received a coronary stent within the last 6 months.
  4. Intolerance or to acetylsalicylic acid (ASA).
  5. Any contraindication to anticoagulant therapy.
  6. Major bleeding within the last 6 months (other than gastrointestinal (GI) hemorrhage).
  7. Severe renal impairment (estimated (GFR) =\< 30 mL/min).
  8. Uncontrolled hypertension (SBP > 180 mmHg and/or DBP > 100 mmHg).
  9. Abnormal liver function as defined by aspartat-aminotransferase (), alanin-aminotransferase (ALT), serum or alkaline phosphatase (AP) above the reference range, or history of liver disease.
  10. Women who are pregnant or of who refuses to use a medically acceptable form of throughout the study.
  11. Patients who have received an drug within the last 30 days.
  12. Patients scheduled for major surgery or invasive procedures which may cause bleeding, or those who have had major surgery or percutaneous coronary intervention (PCI) within 6 weeks.
  13. Patients considered unreliable by the investigator.
  14. Another indication for anticoagulant treatment.
  15. Patients suffering from anemia.
  16. Patients suffering from thrombocytopenia.
  17. Any other condition which, in the discretion of the investigator, would not allow safe participation in the study.
  18. Concomitant treatment with antiplatelet agents other than ASA.
  19. Recent or radiation therapy (=\< 6 month).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
502 participants (actual)

Study arms

  • Experimental
    dabigatran 50 mg twice daily (bid)

    Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).

    Drug: dabigatran without ASA

  • Experimental
    dabigatran 50 mg bid + 81 mg ASA qd

    Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.

    Drug: dabigatran with ASA

  • Experimental
    dabigatran 50 mg bid + 325 mg ASA qd

    Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning

    Drug: dabigatran with ASA

  • Experimental
    dabigatran 150 mg bid

    Dabigatran: one capsule in the morning and 1 capsule in the evening

    Drug: dabigatran without ASA

  • Experimental
    dabigatran 150 mg bid + 81 mg ASA qd

    Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning

    Drug: dabigatran with ASA

  • Experimental
    dabigatran 150 mg bid + 325 mg ASA qd

    Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning

    Drug: dabigatran with ASA

  • Experimental
    dabigatran 300 mg bid

    Dabigatran: one capsule in the morning and 1 capsule in the evening

    Drug: dabigatran without ASA

  • Experimental
    dabigatran 300 mg bid + 81 mg ASA qd

    Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning

    Drug: dabigatran with ASA

  • Experimental
    dabigatran 300 mg bid + 325 mg ASA qd

    Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning

    Drug: dabigatran with ASA

  • Active comparator
    warfarin

    once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0

    Drug: warfarin

Interventions

  • Drugdabigatran with ASA

    Drug pages: Dabigatran · Aspirin

    dose comparison in combination

  • Drugdabigatran with ASA

    Drug pages: Dabigatran · Aspirin

    dose comparison in combination

  • Drugdabigatran with ASA

    Drug pages: Dabigatran · Aspirin

    dose comparison in combination

  • Drugdabigatran with ASA

    Drug pages: Dabigatran · Aspirin

    dose comparison in combination

  • Drugdabigatran with ASA

    Drug pages: Dabigatran · Aspirin

    dose comparison in combination

  • Drugdabigatran with ASA

    Drug pages: Dabigatran · Aspirin

    dose comparison in combination

  • comparator

  • Drugdabigatran without ASA

    dose comparison

  • Drugdabigatran without ASA

    dose comparison

  • Drugdabigatran without ASA

    dose comparison

06

What researchers measure

Primary outcomes

  1. Number of Participants With Fatal or Life-threatening Major Bleeding Events

    Retroperitoneal, intracranial, intraocular, or intraspinal bleeding, or requiring surgical treatment, or leading to a transfusion of 2 units or more, or leading to a fall in hemoglobin of 20g/L or more

    Time frame: 12 weeks

  2. Number of Participants With Minor/Relevant Bleeding Events

    Haematuria, rectal bleeding, gingival bleeding, skin hematoma of 25cm\^2 or more, nose bleed of more than 5 minutes duration, bleeding leading to a hospitalization, leading to a transfusion of less than 2 units or any other clinically relevant bleeding

    Time frame: 12 weeks

  3. Number of Participants With Minor/Nuisance Bleeding Events

    All bleeding events not fulfilling one of the criteria for major bleeding event or minor/relevant bleeding events.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Participants With Thromboembolic Events: Composite Endpoint

    Combination of ischemic stroke (fatal or non fatal), transient ischemic attack, systemic thromboembolism, myocardial infarction (fatal or non fatal), other major adverse cardiac event and all cause mortality

    Time frame: 12 weeks

  2. Number of Participants With Thromboembolic Events: Ischemic Stroke

    Occurence of an ischemic stroke (fatal or non-fatal)

    Time frame: 12 weeks

  3. Thromboembolic Events: Number of Participants With Transient Ischemic Attack

    Occurence of a transient ischemic attack

    Time frame: 12 weeks

  4. Thromboembolic Events: Number of Participants With Systemic Thromboembolism

    Occurence of a systemic thromboembolism

    Time frame: 12 weeks

  5. Thromboembolic Events: Number of Participants With Myocardial Infarction

    Occurence of a myocardial infarction

    Time frame: 12 weeks

  6. Thromboembolic Events: Number of Participants With Other Major Cardiac Events

    Occurence of other major adverse cardiac events

    Time frame: 12 weeks

  7. Thromboembolic Events: Number of Participants Who Died

    Occurence of death by all causes

    Time frame: 12 weeks

  8. D-dimer: Difference From Baseline

    Difference in D-dimer from baseline to last available value

    Time frame: baseline and 12 weeks

  9. Soluble Fibrin: Difference From Baseline

    Difference from baseline to visit 7

    Time frame: baseline and 12 weeks

  10. 11-dehydrothromboxane B2 (TXB2): Difference From Baseline

    Difference from baseline to visit 7

    Time frame: baseline and 12 weeks

  11. Ecarin Clotting Time (ECT): Difference From Baseline

    Time frame: baseline and 12 weeks

  12. Activated Partial Thromboplastin Time (aPTT): Difference From Baseline

    Time frame: baseline and 12 weeks

  13. Trough Plasma Concentration of Dabigatran (BIBR 953)

    The values of the trough plasma concentration of dabigatran (BIBR 953) are the by-patient geometric means of week 1, 4 and 12.

    Time frame: 12 weeks

  14. Number of Participants With Increase of Aspartat-Aminotransferase (AST) to >2*Baseline

    Increase of AST to more than two times the baseline value

    Time frame: 12 weeks

  15. Number of Participants With Increase of Alkaline Phosphatase (AP) to >2*Baseline

    Increase of AP to more than two times the baseline value

    Time frame: 12 weeks

  16. Number of Participants With Increase of Bilirubin to >2*Baseline

    Increase of Bilirubin to more than two times the baseline value

    Time frame: 12 weeks

  17. Number of Participants With Increase of Alanine-Aminotransferase (ALT) to >2*Baseline

    Number of Participants with Increase of ALT to more than two times the baseline value

    Time frame: 12 weeks

  18. Severity of Adverse Events

    Total number of patients with any adverse event of worst intensity 'mild', 'moderate' and 'severe'.

    Time frame: 12 weeks

07

Results

Posted Feb 10, 2011

Participant flow

Participant flow — Overall Study
MilestoneBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Started58202799343398333070
Completed56182691323290272468
Not completed2218218662
Withdrew: Adverse event2216116640
Withdrew: Protocol violation0001000000
Withdrew: Lost to follow-up0000100000
Withdrew: Withdrawal by subject0000002001
Withdrew: Other0001000021

Outcome measures

PrimaryNumber of Participants With Fatal or Life-threatening Major Bleeding Events

Retroperitoneal, intracranial, intraocular, or intraspinal bleeding, or requiring surgical treatment, or leading to a transfusion of 2 units or more, or leading to a fall in hemoglobin of 20g/L or more

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Fatal or Life-threatening Major Bleeding Events
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Number of Participants With Fatal or Life-threatening Major Bleeding Events0000000130
PrimaryNumber of Participants With Minor/Relevant Bleeding Events

Haematuria, rectal bleeding, gingival bleeding, skin hematoma of 25cm\^2 or more, nose bleed of more than 5 minutes duration, bleeding leading to a hospitalization, leading to a transfusion of less than 2 units or any other clinically relevant bleeding

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Minor/Relevant Bleeding Events
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Number of Participants With Minor/Relevant Bleeding Events0119226434
PrimaryNumber of Participants With Minor/Nuisance Bleeding Events

All bleeding events not fulfilling one of the criteria for major bleeding event or minor/relevant bleeding events.

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Minor/Nuisance Bleeding Events
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Number of Participants With Minor/Nuisance Bleeding Events2126659799
SecondaryNumber of Participants With Thromboembolic Events: Composite Endpoint

Combination of ischemic stroke (fatal or non fatal), transient ischemic attack, systemic thromboembolism, myocardial infarction (fatal or non fatal), other major adverse cardiac event and all cause mortality

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Thromboembolic Events: Composite Endpoint
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Number of Participants With Thromboembolic Events: Composite Endpoint1210000000
SecondaryNumber of Participants With Thromboembolic Events: Ischemic Stroke

Occurence of an ischemic stroke (fatal or non-fatal)

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Thromboembolic Events: Ischemic Stroke
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
None58192799343398333070
Fatal0000000000
Non-Fatal0100000000
Both0000000000
SecondaryThromboembolic Events: Number of Participants With Transient Ischemic Attack

Occurence of a transient ischemic attack

Time frame:
12 weeks
Reported as:
Number · Participants
Thromboembolic Events: Number of Participants With Transient Ischemic Attack
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Thromboembolic Events: Number of Participants With Transient Ischemic Attack0000000000
SecondaryThromboembolic Events: Number of Participants With Systemic Thromboembolism

Occurence of a systemic thromboembolism

Time frame:
12 weeks
Reported as:
Number · Participants
Thromboembolic Events: Number of Participants With Systemic Thromboembolism
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Thromboembolic Events: Number of Participants With Systemic Thromboembolism1100000000
SecondaryThromboembolic Events: Number of Participants With Myocardial Infarction

Occurence of a myocardial infarction

Time frame:
12 weeks
Reported as:
Number · Participants
Thromboembolic Events: Number of Participants With Myocardial Infarction
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
None58202799343398333070
Fatal0000000000
Non-Fatal0000000000
Both0000000000
SecondaryThromboembolic Events: Number of Participants With Other Major Cardiac Events

Occurence of other major adverse cardiac events

Time frame:
12 weeks
Reported as:
Number · Participants
Thromboembolic Events: Number of Participants With Other Major Cardiac Events
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Thromboembolic Events: Number of Participants With Other Major Cardiac Events0110000000
SecondaryThromboembolic Events: Number of Participants Who Died

Occurence of death by all causes

Time frame:
12 weeks
Reported as:
Number · Participants
Thromboembolic Events: Number of Participants Who Died
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Thromboembolic Events: Number of Participants Who Died0000000000
SecondaryD-dimer: Difference From Baseline

Difference in D-dimer from baseline to last available value

Time frame:
baseline and 12 weeks
Reported as:
Mean · ng/ml
D-dimer: Difference From Baseline
ng/mlBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
D-dimer: Difference From Baseline22.3 ± 65.412.3 ± 25.350.2 ± 182.88.1 ± 41.629.1 ± 90.48.6 ± 49.24.2 ± 95.811.3 ± 82.2-7.9 ± 40.9-5.8 ± 50.6
Statistical analysis
  • BIBR 1048 50 mg b.i.d vs BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. vs BIBR 1048 50 mg b.i.d + ASA 325 mg qd vs BIBR 1048 150 mg b.i.d vs BIBR 1048 150 mg b.i.d + ASA 81 mg qd vs BIBR 1048 150 mg b.i.d + ASA 325 mg qd vs BIBR 1048 300 mg b.i.d vs BIBR 1048 300 mg b.i.d + ASA 81 mg qd vs BIBR 1048 300 mg b.i.d + ASA 325 mg qd vs Warfarin, Dosed to Target INR 2.0 to 3.0 · Kruskal-Wallis · p = 0.0357
SecondarySoluble Fibrin: Difference From Baseline

Difference from baseline to visit 7

Time frame:
baseline and 12 weeks
Reported as:
Mean · µg/ml
Soluble Fibrin: Difference From Baseline
µg/mlBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Soluble Fibrin: Difference From Baseline3.2 ± 22.00.9 ± 2.31.2 ± 8.40.3 ± 5.1-2.0 ± 9.9-1.3 ± 8.82.3 ± 26.8-0.7 ± 4.6-1.9 ± 12.00.1 ± 4.0
Statistical analysis
  • BIBR 1048 50 mg b.i.d vs BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. vs BIBR 1048 50 mg b.i.d + ASA 325 mg qd vs BIBR 1048 150 mg b.i.d vs BIBR 1048 150 mg b.i.d + ASA 81 mg qd vs BIBR 1048 150 mg b.i.d + ASA 325 mg qd vs BIBR 1048 300 mg b.i.d vs BIBR 1048 300 mg b.i.d + ASA 81 mg qd vs BIBR 1048 300 mg b.i.d + ASA 325 mg qd vs Warfarin, Dosed to Target INR 2.0 to 3.0 · Kruskal-Wallis · p = 0.26711
Secondary11-dehydrothromboxane B2 (TXB2): Difference From Baseline

Difference from baseline to visit 7

Time frame:
baseline and 12 weeks
Reported as:
Mean · pg/mg Creatinine
11-dehydrothromboxane B2 (TXB2): Difference From Baseline
pg/mg CreatinineBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
11-dehydrothromboxane B2 (TXB2): Difference From Baseline596.5 ± 2896.3-1816.8 ± 2186.1-2779.8 ± 2953.3922.0 ± 3874.0-1988.6 ± 2187.5-1125.9 ± 3566.61059.7 ± 2216.8-1822.6 ± 2381.7-1337.8 ± 2279.2203.5 ± 2109.0
SecondaryEcarin Clotting Time (ECT): Difference From Baseline
Time frame:
baseline and 12 weeks
Reported as:
Mean · seconds
Ecarin Clotting Time (ECT): Difference From Baseline
secondsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Ecarin Clotting Time (ECT): Difference From Baseline9.7 ± 8.212.0 ± 10.712.0 ± 9.631.9 ± 26.242.5 ± 29.232.7 ± 23.163.6 ± 44.870.8 ± 60.374.0 ± 70.53.1 ± 2.5
SecondaryActivated Partial Thromboplastin Time (aPTT): Difference From Baseline
Time frame:
baseline and 12 weeks
Reported as:
Mean · seconds
Activated Partial Thromboplastin Time (aPTT): Difference From Baseline
secondsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Activated Partial Thromboplastin Time (aPTT): Difference From Baseline6.4 ± 5.68.3 ± 6.18.8 ± 9.413.5 ± 18.324.9 ± 26.114.5 ± 11.525.0 ± 12.423.4 ± 12.727.2 ± 24.28.8 ± 6.7
SecondaryTrough Plasma Concentration of Dabigatran (BIBR 953)

The values of the trough plasma concentration of dabigatran (BIBR 953) are the by-patient geometric means of week 1, 4 and 12.

Time frame:
12 weeks
Reported as:
Mean · ng/ml
Trough Plasma Concentration of Dabigatran (BIBR 953)
ng/mlBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Trough Plasma Concentration of Dabigatran (BIBR 953)29.1 ± 16.630.4 ± 16.631.8 ± 20.082.8 ± 54.3103.2 ± 69.090.1 ± 52.5188.0 ± 117.3203.7 ± 123.9207.6 ± 108.7NA ± NA
SecondaryNumber of Participants With Increase of Aspartat-Aminotransferase (AST) to >2*Baseline

Increase of AST to more than two times the baseline value

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Increase of Aspartat-Aminotransferase (AST) to >2*Baseline
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Missing0000001101
No57202493323195313068
Yes1036222101
SecondaryNumber of Participants With Increase of Alkaline Phosphatase (AP) to >2*Baseline

Increase of AP to more than two times the baseline value

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Increase of Alkaline Phosphatase (AP) to >2*Baseline
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Missing0000001101
No58202798333397322969
Yes0001100010
SecondaryNumber of Participants With Increase of Bilirubin to >2*Baseline

Increase of Bilirubin to more than two times the baseline value

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Increase of Bilirubin to >2*Baseline
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Missing0000001101
No55182586313388292963
Yes32213309316
SecondaryNumber of Participants With Increase of Alanine-Aminotransferase (ALT) to >2*Baseline

Number of Participants with Increase of ALT to more than two times the baseline value

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Increase of Alanine-Aminotransferase (ALT) to >2*Baseline
ParticipantsBIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0
Missing0000001101
No55182695333293313064
Yes3214114105
SecondarySeverity of Adverse Events

Total number of patients with any adverse event of worst intensity 'mild', 'moderate' and 'severe'.

Time frame:
12 weeks
Reported as:
Number · participants
Severity of Adverse Events
participantsD50bidD50qdD50bid + ASA81qdD50bid + ASA325qdD150bidD150qdD150bid + ASA81qdD150qd + ASA81qdD150bid + ASA325qdD150qd + ASA325qdD300bidD300qdD300bid + ASA81qdD300qd + ASA81qdD300bid + ASA325qdD300qd + ASA325qdWarfarin, Dosed to Target INR 2.0 to 3.0
Mild24091654123017047123223130
Moderate1306719090402305111114
Severe30114020106010202

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
D50bid—5/59 (8.5%)20/59 (33.9%)
D50qd—0/1 (0%)0/1 (0%)
D50bid + ASA81qd—2/21 (9.5%)9/21 (42.9%)
D50bid + ASA325qd—1/27 (3.7%)14/27 (51.9%)
D150bid—10/100 (10%)43/100 (43%)
D150qd—0/3 (0%)1/3 (33.3%)
D150bid + ASA81qd—4/36 (11.1%)19/36 (52.8%)
D150qd + ASA81qd—0/1 (0%)0/1 (0%)
D150bid + ASA325qd—2/33 (6.1%)15/33 (45.5%)
D150qd + ASA325qd—0/1 (0%)0/1 (0%)
D300bid—3/105 (2.9%)35/105 (33.3%)
D300qd—0/3 (0%)1/3 (33.3%)
D300bid + ASA81qd—4/34 (11.8%)20/34 (58.8%)
D300qd + ASA81qd—0/2 (0%)2/2 (100%)
D300bid + ASA325qd—4/30 (13.3%)18/30 (60%)
D300qd + ASA325qd—0/1 (0%)1/1 (100%)
Warfarin—2/70 (2.9%)22/70 (31.4%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventD50bidD50qdD50bid + ASA81qdD50bid + ASA325qdD150bidD150qdD150bid + ASA81qdD150qd + ASA81qdD150bid + ASA325qdD150qd + ASA325qdD300bidD300qdD300bid + ASA81qdD300qd + ASA81qdD300bid + ASA325qdD300qd + ASA325qdWarfarin
Cardiac failureCardiac disorders0/590/10/210/271/1000/32/360/10/330/10/1050/30/340/20/300/10/70
Acute coronary syndromeCardiac disorders0/590/11/210/270/1000/30/360/10/330/10/1050/31/340/20/300/10/70
Atrial thrombosisCardiac disorders0/590/11/210/270/1000/30/360/10/330/10/1050/30/340/20/300/10/70
Cerebrovascular accidentNervous system disorders0/590/11/210/270/1000/30/360/10/330/10/1050/30/340/20/300/10/70
Renal infarctRenal and urinary disorders0/590/11/210/270/1000/30/360/10/330/10/1050/30/340/20/300/10/70
IleusGastrointestinal disorders0/590/10/211/270/1000/30/360/10/330/10/1050/30/340/20/300/10/70
Gastrointestinal haemorrhageGastrointestinal disorders0/590/10/210/270/1000/30/360/10/330/10/1050/31/340/21/300/10/70
Lower gastrointestinal haemorrhageGastrointestinal disorders0/590/10/210/270/1000/30/360/10/330/10/1050/30/340/21/300/10/70
Rectal haemorrhageGastrointestinal disorders0/590/10/210/270/1000/30/360/10/330/10/1050/30/340/21/300/10/70
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/590/10/210/270/1000/30/360/10/330/10/1050/30/340/21/300/10/70
Most frequent other events
Showing 10 of 37
Most frequent other events
EventD50bidD50qdD50bid + ASA81qdD50bid + ASA325qdD150bidD150qdD150bid + ASA81qdD150qd + ASA81qdD150bid + ASA325qdD150qd + ASA325qdD300bidD300qdD300bid + ASA81qdD300qd + ASA81qdD300bid + ASA325qdD300qd + ASA325qdWarfarin
Abdominal distensionGastrointestinal disorders1/590/12/210/271/1000/30/360/10/330/10/1050/30/340/20/301/10/70
DizzinessNervous system disorders3/590/11/213/274/1000/32/360/11/330/14/1050/32/341/25/301/12/70
Abdominal painGastrointestinal disorders1/590/10/210/271/1000/30/360/10/330/12/1050/30/341/20/300/11/70
NauseaGastrointestinal disorders2/590/12/210/274/1000/31/360/11/330/11/1050/32/341/21/300/10/70
VomitingGastrointestinal disorders1/590/10/212/270/1000/30/360/10/330/10/1050/30/341/20/300/10/70
FatigueGeneral disorders1/590/10/212/275/1000/31/360/10/330/13/1050/35/341/21/300/13/70
Sensation of pressureGeneral disorders0/590/10/210/270/1000/30/360/10/330/10/1050/30/341/20/300/10/70
Alanine aminotransferase increasedInvestigations0/590/10/210/270/1000/30/360/10/330/11/1050/30/341/20/300/10/70
Aspartate aminotransferase increasedInvestigations0/590/10/210/270/1000/30/360/10/330/11/1050/30/341/20/300/10/70
CostochondritisMusculoskeletal and connective tissue disorders0/590/10/210/270/1000/30/360/10/330/10/1050/30/341/20/300/10/70

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0Total
Mean69.0 ± 8.870.1 ± 9.471.6 ± 8.169.7 ± 7.772.1 ± 9.069.7 ± 8.069.0 ± 9.171.8 ± 7.268.6 ± 7.169.0 ± 8.369.7 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)BIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0Total
Female1245158819721191
Male46162284262579262859411
Baseline documentation regarding the atrial fibrillation
Baseline documentation regarding the atrial fibrillation(Participants)BIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0Total
Persistent2091043131037141227195
Permanent2391135111637101426192
Paroxysmal152621107249417115
Baseline documentation regarding stroke
Baseline documentation regarding stroke(Participants)BIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0Total
No54182493303091312662459
Yes423643724843
Baseline documentation regarding transient ischemic attack
Baseline documentation regarding transient ischemic attack(Participants)BIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0Total
No49202588313190302663453
Yes9021132834749
Baseline documentation regarding transient ischemic attack or stroke
Baseline documentation regarding transient ischemic attack or stroke(Participants)BIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0Total
No45182382272885282257415
Yes1324177513581387
Baseline documentation regarding hypertension
Baseline documentation regarding hypertension(Participants)BIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0Total
No171082113142481021146
Yes41101978211974252049356
Baseline documentation regarding symptomatic heart failure
Baseline documentation regarding symptomatic heart failure(Participants)BIBR 1048 50 mg b.i.dBIBR 1048 50 mg b.i.d + ASA 81 mg q.d.BIBR 1048 50 mg b.i.d + ASA 325 mg qdBIBR 1048 150 mg b.i.dBIBR 1048 150 mg b.i.d + ASA 81 mg qdBIBR 1048 150 mg b.i.d + ASA 325 mg qdBIBR 1048 300 mg b.i.dBIBR 1048 300 mg b.i.d + ASA 81 mg qdBIBR 1048 300 mg b.i.d + ASA 325 mg qdWarfarin, Dosed to Target INR 2.0 to 3.0Total
No41121773202185202046355
Yes1781026141213131024147

8 further baseline measures are reported on the registry.

08

Study locations

38 sites
  • 1160.20.10010
    Fayetteville, Arkansas, United States
  • 1160.20.10003 La Mesa Cardiac
    La Mesa, California, United States
  • 1160.20.10006 The Ford Research Institute, PA
    Pensacola, Florida, United States
  • 1160.20.10004
    Port Charlotte, Florida, United States
  • 1160.20.10002
    St. Petersburg, Florida, United States
  • 1160.20.10015
    Baltimore, Maryland, United States
  • 1160.20.10008
    Westminister, Maryland, United States
  • 1160.20.10012
    Pittsfield, Massachusetts, United States
  • 1160.20.10007
    Troy, Michigan, United States
  • 1160.20.10014
    Hawthorne, New York, United States
  • 1160.20.10013
    New Hyde Park, New York, United States
  • 1160.20.10009
    North Durham, North Carolina, United States
  • 1160.20.10001
    Philadelphia, Pennsylvania, United States
  • 1160.20.10005
    Germantown, Tennessee, United States
  • 1160.20.45010
    Aalborg, Denmark
  • 1160.20.45005 Aarhus Sygehus
    Aarhus C, Denmark
  • 1160.20.45007 Medicinsk afdeling
    Brædstrup, Denmark
  • 1160.20.45011 Medicinsk afd.
    Esbjerg, Denmark
  • 1160.20.45012 Afdeling B3
    Frederikssund, Denmark
  • 1160.20.45003 Forskningscentret plan 3
    Helsingør, Denmark
  • 1160.20.45004 Herlev Hospital
    Herlev, Denmark
  • 1160.20.45009 Medicinsk amb. B8
    Holbæk, Denmark
  • 1160.20.45002 Kardiologisk afdeling
    Hvidovre, Denmark
  • 1160.20.45014 Hjertemedicinsk afd.
    Køge, Denmark
  • 1160.20.45001 Kardiologisk Laboratorium
    Odense, Denmark
  • 1160.20.45013 Kardiologisk afd.
    Roskilde, Denmark
  • 1160.20.45006 Medicinsk afdeling
    Svendborg, Denmark
  • 1160.20.46013 HIA, Mälarsjukhuset
    Eskilstuna, Sweden
  • 1160.20.46007 Falu Lasarett
    Falun, Sweden
  • 1160.20.46005 Ryhovs Länssjukhus
    Jönköping, Sweden
  • 1160.20.46010 Länssjukhuset Kalmar
    Kalmar, Sweden
  • 1160.20.46009 Universitetssjukhuset MAS
    Malmö, Sweden
  • 1160.20.46008 Vrinnevisjukhuset
    Norrköping, Sweden
  • 1160.20.46002 Södersjukhuset
    Stockholm, Sweden
  • 1160.20.46011 Arytmienheten, Med klin
    Stockholm, Sweden
  • 1160.20.46006 Norrlands Universitetssjukhus
    Umeå, Sweden
  • 1160.20.46003 Centrallasarettet
    Västerås, Sweden
  • 1160.20.46004 Universitetssjukhuset
    Örebro, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003 and a primary completion of Nov 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2010
First posted
Oct 25, 2010
Start
Sep 2003
Primary completionActual
Nov 2004
Results first posted
Feb 10, 2011
Last update
May 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01227629
First posted
Oct 25, 2010
Start date
Sep 2003
Primary completion
Nov 2004
Results posted
Feb 10, 2011
Last update
May 5, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Aspirin

Start the discussion